Nishiyama, Daichi
Chinen, Yoshiaki
Isa, Reiko
Fujibayashi, Yuto
Kuwahara-Ota, Saeko
Yamaguchi, Junko
Takimoto-Shimomura, Tomoko
Matsumura-Kimoto, Yayoi
Tsukamoto, Taku
Shimura, Yuji
Kobayashi, Tsutomu
Horiike, Shigeo
Taniwaki, Masafumi
Handa, Hiroshi
Kuroda, Junya http://orcid.org/0000-0001-6130-1550
Funding for this research was provided by:
National Cancer Center Research and Development Funds (26-A-4, 29-A-3)
Ministry of Health, Labour and Welfare (H26-kakushin-teki-gan-ippan-074)
Japan Agency for Medical Research and Development (JP16ck0106077h003, JP17ck0106348h0001, JP18ck0106348h0002, JP19ck0106348h0003)
Ministry of Education, Culture, Sports, Science and Technology (16K09856, 18K08367)
Japanese Society for Myeloma Research Award
Article History
Received: 6 July 2020
Revised: 3 October 2020
Accepted: 5 October 2020
First Online: 23 October 2020
Compliance with ethical standards
:
: Y.F. is an employee of Nippon Shinyaku. J.K. has received research funding from Bristol-Myers Squibb, Sysmex, Celgene, Ono Pharmaceutical, Otsuka Pharmaceutical, Sanofi, Kyowa Kirin, Chugai Pharmaceutical, Eisai, Astellas Pharma, Dainippon Sumitomo Pharma, Nippon Shinyaku, Takeda, Shionogi, Asahi Kasei, Daiichi Sankyo, MSD, Taiho Pharmaceutical, Fujimoto Pharmaceutical and Pfizer, has received honoraria from Bristol-Myers Squibb, Janssen Pharmaceutical K.K, Celgene Corporation, Ono Pharmaceutical, Takeda, Sanofi, Kyowa Kirin, Chugai Pharmaceutical, Eisai, Astellas Pharma, Nippon Shinyaku, Dainippon Sumitomo Pharma, Daiichi Sankyo, Fujimoto Pharmaceutical, Abbvie and Otsuka Pharmaceutical; and is a consultant for Janssen Pharmaceutical K.K, Celgene, Bristol-Myers Squibb, Sanofi and Abbvie. H.H. has received research funding from Celgene, Takeda, Ono Pharmaceutical, Kyowa Kirin, Sanofi, MSD, Chugai Pharmaceutical, Shionogi, Bayer, Eizai, and Astellas Pharma; has received honoraria from Janssen, Celgene, Takeda, Sanofi and Ono; and is a consultant for Janssen, Takeda and Celgene. M.T. has received research funding from Kyowa Kirin, Chugai Pharmaceutical, Eisai, and Astellas Pharma. T.K. has received honoraria from Chugai Pharmaceutical, Ono Pharmaceutical, Eisai, and Nippon Shinyaku. T.T. has received research funding from Nippon Shinyaku. Others have no conflict of interest.